FDA expands approval of Novartis’ Gilenya to treat MS in pediatric patients

This article was originally published here

Novartis has secured an expanded approval of Gilenya (fingolimod) in the US for the treatment of children and adolescents, in the age group of 10-18 years, with relapsing forms of multiple sclerosis (RMS).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply